Life and death on the posterior capsule

Article

The UK?s Professor John Marshall looks at the evolution of excimer delivery systems.

Whilst posterior capsule opacification (PCO) rates had been dramatically reduced in the past few years thanks to IOL design and development there was still a great deal of work to be done in addressing what remains the common complication following implant and cataract surgery, according to Dr David Spalton who delivered the Ridley Medal Lecture at ESCRS in Paris.

Life and death on the posterior capsule was the theme of his talk and he addressed the strides made since Harold Ridley implanted the very first IOL in 1949 from realizing that PCO was not an inevitable result of the procedure, that square edge profiles made a difference in prevention and that resistance was best offered by a 360 degree square edged barrier on the IOL so that lens ephithelial cells could not migrate across the optic-haptic onto the posterior capsule.

Dr Spalton also acknowledged that as the trend towards microincision surgery increased manufacturers were concentrating on developing thinner-edged lenses to insert in a small incision but this was at the expense of incorporating a 360 degree square edged barrier. He predicted that this trend would not be reversible and that the answer to further reduction in PCO rates would emerge from elsewhere. Research to achieve this currently includes isolation of the lens epithelial cells, a means of destroying them completely or removing them by means of an open bag device.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.